For a quarter of a century, Novartis and The Max Foundation have worked together to provide access to cancer care.
About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs 1 Clinically relevant 15.2% ...
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...
Novartis’ commitment to kidney diseases Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, ...
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US ...
Nürnberg, 5. Mai 2026 – Novartis hat heute Pläne bekannt gegeben, den Produktionsstandort in Wehr bis voraussichtlich Ende 2028 zu schließen. In Wehr werden feste orale Darreichungsformen – Tabletten ...
～2歳未満を対象としたゾルゲンスマ ® 点滴静注に次ぐ、SMAの新たな治療選択肢～ ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下 ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients East Hanover, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results